FDA Forming Consortium to Study Gene Biomarkers Linked to Serious Adverse Events | GenomeWeb
NEW YORK (GenomeWeb News) — The US Food and Drug Administration is creating a consortium with members of the pharmaceutical industry and academia that aims to observe how genetic biomarkers contribute to serious adverse events, according to an NIH report and people familiar with the project.
 
The FDA’s decision to form the initiative, called the Serious Adverse Events Consortium, comes at a time when a chorus of critics increasingly blames the agency for not doing enough to ensure the safety of marketed drugs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.